Riskpilot← Back to searchSign inGet full accessTermino C 12138 AB
ABDissolvedOrg 5562509470Wholesale of pharmaceutical and medical goods · NACE 4646Est. 19840 employees
Revenue 2023
SEK 0
EBITDA margin
—
+3% vs 2022
Equity ratio
99.3%
Financial strength
Net profit 2023
SEK -864K
+16% vs 2022
| Revenue | SEK 0 | — |
| EBITDA | SEK -876K | +3% |
| Net profit | SEK -864K | +16% |
| Total assets | SEK 1,4M | -39% |
| Equity | SEK 1,3M | -39% |
| Employees | 0 | — |
Legal name
Termino C 12138 AB
Org number
5562509470
Legal form
Aktiebolag
NACE code
4646 · Wholesale of pharmaceutical and medical goods
Founded
13 december 1984
Share capital
SEK 1 000 274
Employees
0
VAT registered
No
Audit selected
No
Last report
2023-12-31
Financial year
January – December
Signatory rights
Firman tecknas av styrelsen Firman tecknas var för sig av ledamoten suppleanten
Company purpose
Aktiebolaget skall bedriva förvaltning av värdepapper samt därmed jämförlig verksamhet.
Address
Risika for professionals
Risika provides regulated workflow tools for finance, procurement and compliance teams that need monitoring, alerts and an API.
| Item | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 | 0 |
| Staff expenses | — | — | — | −870 | −857 |
| EBITDA | −314 | −1 069 | −865 | −900 | −876 |
| Depreciation & amort. | −0 | −0 | −0 | — | — |
| EBIT | −314 | −1 069 | −865 | −900 | −876 |
| Net financials | −2 750 | −1 774 | −2 | −128 | 12 |
| Profit before tax | −1 689 | −1 956 | −867 | −1 028 | −864 |
| Tax | −0 | −0 | −0 | — | — |
| Net profit | −1 689 | −1 956 | −867 | −1 028 | −864 |
| Item | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|
| Total assets | 6 089 | 4 129 | 3 247 | 2 219 | 1 360 |
| Equity | 6 064 | 4 108 | 3 241 | 2 213 | 1 350 |
| Long-term debt | 0 | 0 | 0 | — | — |
| Short-term debt | 25 | 21 | 6 | 6 | 10 |
| Total debt | 25 | 21 | 6 | 6 | 10 |
EBITDA margin
-87579100.0%
This company
15.8%
Market median
-554298201% vs market
20192023
Equity ratio
99.3%
This company
38.2%
Market median
+160% vs market
20192023
Return on equity
-64.0%
This company
18.4%
Market median
-448% vs market
20192023
Net profit margin
-86350100.0%
This company
8.1%
Market median
-1066050717% vs market
20192023
Asset turnover
0.00×
This company
1.12×
Market median
-100% vs market
20192023
Debt / equity
0.01×
This company
0.62×
Market median
+98% vs market
20192023
- Annual report 2023Filed via Bolagsverket / SCB · Period 2023-01-01 – 2023-12-31
- Annual report 2022Filed via Bolagsverket / SCB · Period 2022-01-01 – 2022-12-31
- Annual report 2021Filed via Bolagsverket / SCB · Period 2021-01-01 – 2021-12-31
- Annual report 2020Filed via Bolagsverket / SCB · Period 2020-01-01 – 2020-12-31
- Annual report 2019Filed via Bolagsverket / SCB · Period 2019-01-01 – 2019-12-31
| Name | Role | Member since |
|---|---|---|
| Former (1) | ||
LG Chief Executive Officer | Chief Executive Officer | 2022 – 2024 |
| Name | Role | Member since |
|---|---|---|
| Current (2) | ||
| Deputy Board Member | 2024 | |
| Board of Directors | 2024 | |
| Former (1) | ||
| Deputy Board Member | 2022 – 2024 | |
No shareholder data available.
Beneficial ownership (UBO) data access is restricted in Denmark as of September 2025 per the EU 6th AML Directive. Learn more.
No registered parent or subsidiaries
Board members of Termino C 12138 AB also hold positions in 0 other companies.
| Person | Role here | Other companies |
|---|---|---|
| Leif Georg Lind | Chief Executive Officer | 0 companies |
| Anders Jakob Lindquist | Deputy Board Member | 0 companies |
| Kjell Eric Lind | Deputy Board Member | 0 companies |
| Torbjörn Nordberg | Board of Directors | 0 companies |